DoD awards $53.6M for COVID-19 rapid tests to Orasure Technologies under full and open competition

Contract Overview

Contract Amount: $53,640,000 ($53.6M)

Contractor: Orasure Technologies Inc

Awarding Agency: Department of Defense

Start Date: 2022-12-22

End Date: 2023-05-11

Contract Duration: 140 days

Daily Burn Rate: $383.1K/day

Competition Type: FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: 8509606733!INTELISWAB COVID-19 RAPID TE

Place of Performance

Location: BETHLEHEM, NORTHAMPTON County, PENNSYLVANIA, 18015

State: Pennsylvania Government Spending

Plain-Language Summary

Department of Defense obligated $53.6 million to ORASURE TECHNOLOGIES INC for work described as: 8509606733!INTELISWAB COVID-19 RAPID TE Key points: 1. Significant award for critical medical supplies during a public health event. 2. Competition method suggests a potentially competitive market for these diagnostics. 3. Fixed-price contract aims to control costs, but delivery timeline is tight. 4. Sector focus on In-Vitro Diagnostic Substance Manufacturing highlights a key area of defense readiness.

Value Assessment

Rating: good

The award amount of $53.6M for rapid COVID-19 tests appears reasonable given the scale and urgency. Benchmarking against similar large-scale procurements for diagnostic kits would provide further validation.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under 'FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES,' indicating that while initial sources may have been limited, the final award was made through a competitive process. This method generally promotes price discovery and value.

Taxpayer Impact: The use of full and open competition is intended to secure the best value for taxpayers by leveraging market forces.

Public Impact

Ensures availability of critical COVID-19 testing supplies for military personnel and potentially other government entities. Supports the ongoing public health response by providing necessary diagnostic tools. Demonstrates government's commitment to procuring essential medical equipment through established procurement channels.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Positive Signals

Sector Analysis

The procurement falls within the Healthcare sector, specifically In-Vitro Diagnostic Substance Manufacturing. Spending in this area is crucial for national health security and readiness, with benchmarks varying based on technology and scale.

Small Business Impact

The data does not indicate specific set-asides for small businesses. Further analysis would be needed to determine if small businesses had an opportunity to participate in this procurement.

Oversight & Accountability

The award was made by the Defense Logistics Agency, a key component of the Department of Defense responsible for logistics. Oversight would involve monitoring contract performance, delivery schedules, and adherence to quality standards.

Related Government Programs

Risk Flags

Tags

in-vitro-diagnostic-substance-manufactur, department-of-defense, pa, delivery-order, 10m-plus

Frequently Asked Questions

What is this federal contract paying for?

Department of Defense awarded $53.6 million to ORASURE TECHNOLOGIES INC. 8509606733!INTELISWAB COVID-19 RAPID TE

Who is the contractor on this award?

The obligated recipient is ORASURE TECHNOLOGIES INC.

Which agency awarded this contract?

Awarding agency: Department of Defense (Defense Logistics Agency).

What is the total obligated amount?

The obligated amount is $53.6 million.

What is the period of performance?

Start: 2022-12-22. End: 2023-05-11.

What is the specific type of rapid COVID-19 test procured and its intended use case within the DoD?

The specific type of rapid COVID-19 test is not detailed in the provided data. However, given the awardee's expertise in diagnostics and the context of a large DoD procurement, it is likely a point-of-care or self-administered test designed for rapid screening of military personnel. Its intended use would be for maintaining force health protection, enabling timely medical decisions, and supporting operational readiness by quickly identifying potential infections.

How does the per-unit cost of these rapid tests compare to commercially available options or other government contracts?

Without specific unit cost data or detailed product specifications, a direct comparison is challenging. However, the total award of $53.6 million over a 140-day period suggests a significant volume. The 'full and open competition' aspect implies that pricing was vetted against market rates. A detailed cost analysis would require comparing the negotiated price per test against similar large-volume government procurements or bulk commercial pricing for comparable diagnostic technologies.

What are the key performance indicators (KPIs) for ensuring the effectiveness and timely delivery of these diagnostic tests?

Key performance indicators would likely include test sensitivity and specificity rates to ensure diagnostic accuracy, as well as turnaround time for results. For delivery, KPIs would focus on on-time delivery percentages, order fulfillment accuracy, and adherence to the specified delivery schedule (2022-12-22 to 2023-05-11). Contractual clauses would outline remedies for failure to meet these KPIs, ensuring both product quality and logistical efficiency.

Industry Classification

NAICS: ManufacturingPharmaceutical and Medicine ManufacturingIn-Vitro Diagnostic Substance Manufacturing

Product/Service Code: INSTRUMENTS AND LABORATORY EQPT

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 220 E 1ST ST, BETHLEHEM, PA, 18015

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $53,640,000

Exercised Options: $53,640,000

Current Obligation: $53,640,000

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: SPE2DE23D0010

IDV Type: IDC

Timeline

Start Date: 2022-12-22

Current End Date: 2023-05-11

Potential End Date: 2023-05-11 00:00:00

Last Modified: 2023-07-08

More Contracts from Orasure Technologies Inc

View all Orasure Technologies Inc federal contracts →

Other Department of Defense Contracts

View all Department of Defense contracts →

Explore Related Government Spending